Summit Therapeutics SMMT Common Stock
Common Stock at other companies
Other financials
Where this comes from
Reported directly by Summit Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:CommonStockSharesAuthorized.
The official record: Summit Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Summit Therapeutics's common stock.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Summit Therapeutics's common stock?
- Summit Therapeutics (SMMT) reported common stock of 1B in Q1 2026.
- How has Summit Therapeutics's common stock changed year-over-year?
- Summit Therapeutics's common stock decreased by 0.0% year-over-year, from 1B to 1B.
- What is the long-term trend for Summit Therapeutics's common stock?
- Over 5 years (2020 to 2025), Summit Therapeutics's common stock has grown at a 313.6% compound annual growth rate (CAGR), from 826K to 1B.
- What does common stock mean?
- The par value of the company's basic ownership shares.
- How do you interpret common stock?
- Changes in this value typically reflect stock issuances or buybacks, impacting the company's total equity base.
- How does common stock compare across companies?
- Standard equity line item found on all public company balance sheets.